The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AEZS | -29.19% | -92.63% | -40.65% | -100% |
| S&P | +14.84% | +96.04% | +14.41% | +387% |
Æterna Zentaris, Inc. is a specialty biopharmaceutical company, which engages in the development and commercialization of therapeutics and diagnostic tests. Its product Macimorelin, is an oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency. The company was founded on September 12, 1990 and is headquartered in Charleston, SC.
Following three months of examining the 12 most-diagnosed cancers, these stocks look like your best investment choices.
Cancer research is big business, and it pays to know where research dollars are headed.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.75M | 17.6% |
| Gross Profit | $0.97M | 18.9% |
| Gross Margin | 35.43% | 0.4% |
| Market Cap | $10.70M | -20.9% |
| Market Cap / Employee | $0.27M | 0.0% |
| Employees | 40 | 0.0% |
| Net Income | -$2.70M | -89.9% |
| EBITDA | -$2.07M | 38.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $9.33M | -66.4% |
| Accounts Receivable | $2.78M | 124.8% |
| Inventory | 1.8 | -40.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.05M | 60.1% |
| Short Term Debt | $0.21M | -48.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -48.56% | -13.4% |
| Return On Invested Capital | -46.81% | -59.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4.62M | -2411.7% |
| Operating Free Cash Flow | -$4.56M | -966.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.09 | 0.43 | 0.44 | 1.05 | 919.83% |
| Price to Sales | 2.67 | 1.12 | 1.04 | 1.14 | -71.57% |
| Price to Tangible Book Value | 0.09 | 0.47 | 0.48 | 1.05 | 919.83% |
| Enterprise Value to EBITDA | 1.56 | 1.76 | 0.65 | -1.77 | -136.70% |
| Return on Equity | -80.2% | -125.4% | -152.0% | -113.1% | 84.45% |
| Total Debt | $1.62M | $2.31M | $2.23M | $2.26M | 33.85% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
